ADPT
Adaptive Biotechnologies Corporation NASDAQ Listed Jun 27, 2019$14.69
Mkt Cap $2.4B
52w Low $8.50
50.5% of range
52w High $20.76
50d MA $14.26
200d MA $14.96
P/E (TTM)
-36.6x
EV/EBITDA
-89.6x
P/B
9.6x
Debt/Equity
1.3x
ROE
-27.2%
P/FCF
-50.3x
RSI (14)
—
ATR (14)
—
Beta
2.30
50d MA
$14.26
200d MA
$14.96
Avg Volume
2.0M
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
1165 Eastlake Avenue East · Seattle, WA 98109 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | AMC | -0.19 | -0.09 | +52.6% | 16.47 | +8.2% | -4.3% | +0.6% | -1.4% | -0.1% | -0.5% | — |
| Nov 5, 2025 | AMC | -0.16 | -0.15 | +6.2% | 17.59 | -3.6% | -11.5% | -4.9% | -0.5% | -1.2% | -0.2% | — |
| Aug 5, 2025 | AMC | -0.24 | -0.17 | +29.2% | 11.05 | +11.8% | +5.8% | +7.3% | -2.7% | -0.4% | +4.2% | — |
| May 1, 2025 | AMC | -0.28 | -0.20 | +28.6% | 7.36 | +19.7% | +33.7% | +1.9% | -12.2% | +0.0% | +5.2% | — |
| Feb 11, 2025 | AMC | -0.27 | -0.23 | +14.8% | 7.80 | -3.2% | -3.2% | +12.8% | -2.2% | -0.7% | +1.2% | — |
| Nov 7, 2024 | AMC | -0.30 | -0.22 | +26.7% | 5.63 | +6.6% | +3.4% | +11.5% | -8.6% | -1.3% | -4.6% | — |
| Aug 1, 2024 | AMC | -0.32 | -0.26 | +18.8% | 4.45 | -9.0% | -3.4% | +0.5% | +6.7% | -9.1% | +5.0% | — |
| May 7, 2024 | AMC | -0.35 | -0.33 | +5.7% | 3.11 | +8.0% | +2.3% | +11.9% | -1.7% | +8.6% | +4.2% | — |
| Feb 14, 2024 | AMC | -0.32 | -0.30 | +6.2% | 3.94 | -8.6% | +0.5% | -2.8% | +0.0% | -0.8% | +1.6% | — |
| Nov 9, 2023 | AMC | -0.32 | -0.35 | -9.4% | 4.29 | -10.7% | -18.2% | -1.6% | +18.4% | +4.6% | -5.8% | — |
| Aug 2, 2023 | AMC | -0.33 | -0.33 | +0.0% | 7.96 | -4.0% | -12.4% | -2.0% | -1.9% | -0.7% | -2.4% | — |
| May 3, 2023 | AMC | -0.34 | -0.40 | -17.6% | 7.50 | -10.0% | -14.3% | -1.2% | +3.9% | +6.2% | +1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6 | BTIG | Maintains | Buy → Buy | — | $16.47 | $17.82 | +8.2% | -4.3% | +0.6% | -1.4% | -0.1% | -0.5% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $16.47 | $17.82 | +8.2% | -4.3% | +0.6% | -1.4% | -0.1% | -0.5% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $18.55 | $18.52 | -0.2% | +3.1% | +0.6% | -3.8% | -0.7% | +0.7% |
| Nov 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $14.71 | $14.65 | -0.4% | -1.2% | -0.2% | -2.5% | -0.3% | -2.8% |
| Nov 6 | BTIG | Maintains | Buy → Buy | — | $17.59 | $16.95 | -3.6% | -11.5% | -4.9% | -0.5% | -1.2% | -0.2% |
| Nov 6 | JP Morgan | Maintains | Overweight → Overweight | — | $17.59 | $16.95 | -3.6% | -11.5% | -4.9% | -0.5% | -1.2% | -0.2% |
| Oct 22 | BTIG | Maintains | Buy → Buy | — | $17.35 | $17.02 | -1.9% | -5.2% | +4.3% | +0.3% | -0.6% | -1.3% |
| Oct 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.58 | $16.00 | +2.7% | +9.8% | +0.9% | -5.6% | +9.4% | -2.7% |
| Oct 13 | JP Morgan | Maintains | Overweight → Overweight | — | $15.17 | $15.50 | +2.2% | +2.2% | +0.5% | +9.8% | +0.9% | -5.6% |
| Aug 6 | TD Cowen | Maintains | Buy → Buy | — | $11.05 | $12.35 | +11.8% | +5.8% | +7.3% | -2.7% | -0.4% | +4.2% |
| Aug 6 | JP Morgan | Maintains | Overweight → Overweight | — | $11.05 | $12.35 | +11.8% | +5.8% | +7.3% | -2.7% | -0.4% | +4.2% |
| Aug 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.05 | $12.35 | +11.8% | +5.8% | +7.3% | -2.7% | -0.4% | +4.2% |
| May 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.03 | $10.00 | -0.3% | -12.2% | +0.0% | +5.2% | -2.6% | +5.3% |
| May 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.84 | $9.80 | -0.4% | +1.9% | -12.2% | +0.0% | +5.2% | -2.6% |
| May 2 | Goldman Sachs | Maintains | Buy → Buy | — | $7.36 | $8.81 | +19.7% | +33.7% | +1.9% | -12.2% | +0.0% | +5.2% |
| Mar 21 | Goldman Sachs | Upgrade | Neutral → Buy | — | $7.75 | $8.05 | +3.9% | +8.4% | +3.1% | -2.8% | -2.1% | -0.2% |
| Feb 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.37 | $8.39 | +0.2% | -0.5% | -0.7% | +1.8% | +0.0% | -0.7% |
| Feb 13 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $7.55 | $7.65 | +1.3% | +12.8% | -2.2% | -0.7% | +1.2% | -0.5% |
| Jan 28 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.70 | $7.73 | +0.4% | +1.9% | -1.8% | +1.9% | -1.4% | -0.6% |
| Dec 18 | BTIG | Maintains | Buy → Buy | — | $6.52 | $6.63 | +1.7% | -8.4% | +0.5% | +6.5% | -1.1% | +1.1% |
| Nov 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.82 | $6.00 | +3.1% | +11.5% | -8.6% | -1.3% | -4.6% | -9.0% |
| Oct 2 | BTIG | Maintains | Buy → Buy | — | $5.02 | $5.07 | +1.0% | +2.4% | -1.6% | +9.1% | -2.0% | -3.0% |
| Aug 2 | JP Morgan | Maintains | Overweight → Overweight | — | $4.45 | $4.05 | -9.0% | -3.4% | +0.5% | +6.7% | -9.1% | +5.0% |
| May 8 | JP Morgan | Maintains | Overweight → Overweight | — | $3.11 | $3.36 | +8.0% | +2.3% | +11.9% | -1.7% | +8.6% | +4.2% |
| Apr 4 | BTIG | Maintains | Buy → Buy | — | $2.68 | $2.71 | +1.1% | +1.9% | -5.5% | +9.7% | +3.5% | -8.9% |
| Feb 16 | Goldman Sachs | Maintains | Neutral → Neutral | — | $3.96 | $3.91 | -1.3% | -2.8% | +0.0% | -0.8% | +1.6% | +4.1% |
| Feb 15 | JP Morgan | Maintains | Overweight → Overweight | — | $3.94 | $3.60 | -8.6% | +0.5% | -2.8% | +0.0% | -0.8% | +1.6% |
| Nov 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.51 | $3.42 | -2.6% | -1.6% | +18.4% | +4.6% | -5.8% | +6.9% |
| Oct 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.18 | $4.19 | +0.2% | +12.2% | -8.7% | +3.9% | -4.4% | +1.9% |
| Oct 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.29 | $4.24 | -1.1% | +1.8% | +1.8% | -6.5% | -1.7% | +1.0% |
| Aug 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.70 | $6.60 | -1.5% | -0.7% | -2.4% | -1.1% | -1.9% | -0.6% |
| Aug 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $6.97 | $7.19 | +3.2% | -2.0% | -1.9% | -0.7% | -2.4% | -1.1% |
| May 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $6.43 | $6.52 | +1.4% | -1.2% | +3.9% | +6.2% | +1.6% | -4.6% |
| Feb 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.03 | $9.91 | -1.2% | -4.0% | -1.3% | -7.4% | +0.3% | -2.2% |
| Dec 21 | Piper Sandler | Upgrade | Neutral → Overweight | — | $7.09 | $7.82 | +10.3% | +13.5% | +0.1% | -6.9% | -4.7% | -3.4% |
| Nov 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.89 | $9.07 | +2.0% | -14.7% | +2.6% | -6.8% | +25.0% | +3.1% |
| Oct 26 | Piper Sandler | Maintains | Neutral → Neutral | — | $7.12 | $7.03 | -1.3% | +4.9% | -1.2% | +3.1% | +2.2% | +8.1% |
| Aug 17 | Piper Sandler | Maintains | Neutral → Neutral | — | $11.90 | $11.72 | -1.5% | -2.9% | -3.3% | -5.7% | -1.3% | +3.5% |
| May 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.90 | $7.75 | -1.9% | -5.4% | +0.8% | +0.5% | +8.6% | -4.9% |
| May 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.85 | $8.69 | -1.8% | -7.1% | -12.0% | +0.0% | -10.2% | +5.9% |
| Feb 16 | BTIG | Maintains | Buy → Buy | — | $14.69 | $14.54 | -1.0% | +5.2% | -7.6% | -5.5% | +0.7% | -5.2% |
| Feb 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $14.67 | $15.11 | +3.0% | +0.1% | +5.2% | -7.6% | -5.5% | +0.7% |
| Aug 6 | Goldman Sachs | Maintains | Neutral → Neutral | — | $37.69 | $37.34 | -0.9% | -6.3% | -0.5% | -2.2% | -5.0% | -0.2% |
| May 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $36.60 | $36.53 | -0.2% | -4.4% | -7.9% | +2.9% | -0.7% | +2.2% |
| Mar 3 | Goldman Sachs | Downgrade | Buy → Neutral | — | $53.11 | $52.89 | -0.4% | -5.6% | -12.9% | -3.3% | -9.7% | +7.8% |
| Feb 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $55.31 | $56.65 | +2.4% | +2.3% | +2.3% | -8.3% | -5.6% | -12.9% |
| Nov 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $47.07 | $49.01 | +4.1% | +10.3% | -6.2% | +0.8% | -4.9% | -1.9% |
| May 19 | Guggenheim | Maintains | Buy → Buy | — | $39.30 | $39.89 | +1.5% | +2.0% | +0.6% | -0.7% | +4.2% | -5.6% |
| Nov 4 | Goldman Sachs | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Nov 3 | Goldman Sachs | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | RUBINSTEIN JULIEOff | President and COO | Sell | 19,037 | $14.23 | $271K | 377,802 | +4.21% | +4.72% |
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
OraSure's stabilizing public health funding and near-term catalysts position it for revenue growth and margin expansion, making OSUR attractive for investors seeking profitability turnaround potential.
Mar 30
8-K
Adaptive Biotechnologies Corporation -- 8-K Filing
Adaptive Biotechnologies reported strong fourth quarter and full year 2025 financial results, with CEO Chad Robins highlighting outstanding execution and meaningful business progress.
Feb 5
Data updated apr 24, 2026 10:59am
· Source: massive.com